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Abstract
Background: The glaucomas are generally asymptomatic diseases until they are very advanced.
They affect 2% of the population over 40 years of age and therefore represent a significant public
health issue. There have been a number of attempts to develop quality of life scales for the disease.
This review discusses the pros and cons of these scales and suggests the best of the current ones
for use in a clinical setting.
Methods: Medline, Embase and Google Scholar were searched for relevant articles. No time
period was defined and all types of article were included.
Results: 11 Quality of Life scores were identified that have been used with glaucoma patients.
Conclusion: There is no generally accepted 'best' Quality of Life instrument for use in glaucoma.
Many of the scales are biased towards physical symptoms and do little to address the personal or
social factors of the disease. Further work is needed to produce scales that address all these areas
as well as being simple to administer in a clinical setting.
Which quality of life score is best for glaucoma 
patients and why?
Glaucoma is the term given to the chronic, debilitating,
progressive group of eye disorders that can lead to visual
field loss and blindness. Glaucoma usually produces cer-
tain characteristic visual field defects in the individual's
peripheral, as well as central vision. Due to the intractable
nature of the disease the patient usually spends, following
diagnosis, the rest of their life attending an eye hospital
and taking frequent (daily) ocular anti-hypertensive med-
ication. The treatment has associated side effects, it is
expensive and often inconvenient to instill. It has been
reported that approximately 67 million patients suffer
from glaucoma and roughly 10% of these are blind. It is
therefore not surprising that glaucoma frequently has a
large impact on a patient's quality of life [1].
The diagnosis of glaucoma affects people in different
ways. Some readily accept the diagnosis and are keen to
seek out information [2]. Others are more ignorant and
disappear into the community, only to return years later
with a marked deterioration in their visual function. Most
patients fall in between the two extremes and adhere to
their treatment in the main with little or no understand-
ing of the disease process.
Physicians have long strived to quantify quality of life
(QoL) in patients with glaucoma. The reasons for this
range from understanding of the patients experience of
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trials. However although a number of instruments have
been used/developed it has proved difficult to develop the
idea glaucoma QoL score. Patients can lose quality of life
for a number of reasons. The distress of the diagnosis, the
insidious loss of vision and independence, the problems
with frequent treatment and regular hospital outpatient
appointment reviews. So how do we assess the impact of
the disease on the patient's quality of life? Does the QoL
of life score need to be all encompassing? Should it
include all aspects of the disease process from diagnosis to
death? Unfortunately the QoL scales can be complicated,
non user-friendly and contain a myriad of complex math-
ematics. The aim of this article is to give a narrative review
of the readily available QoL scales, highlight the strengths
and weaknesses of each and suggest which one we find
"best" for our assessing glaucoma patients in clinical prac-
tice.
Review strategy
We searched Medline, Embase and Google Scholar for rel-
evant articles. We did not define any time period or any
type of research (e.g. original, reviews, correspondence).
Keywords used to search were:
Quality of Life Scores, Quality of life scales, QoL, eye dis-
ease, glaucoma.
Articles identified were accessed and references checked
for any other potentially relevant literature.
Eleven pertinent articles pertaining to readily available
glaucoma QoL instruments were identified. The Medical
Outcomes Study (Mos-20) has been incorporated into the
MOS SF-36 questionnaire and therefore excluded from
discussion.
Selecting a QoL scale
When selecting a QoL scale for a glaucoma patient we
might hope the instrument fulfils the following criteria:
1. Ease of use in a clinical setting
2. Contains minimal complex mathematics
3. Allows reproducible data to be obtained
4. Correct underlying principles pertaining to glaucoma
5. Simple understandable questions with unambiguous
answers
There are a number of well-documented tools that have
been used to quantify the subjective status of glaucoma
patients [3,4]. These include:
• Generic instruments i.e. not disease state specific. (SF-36
[5], SIP [6])
• Vision specific instruments (VF-14 [7], NEI-VFQ [8],
NEI-VFQ-25 [9], ADVS [10])
• Glaucoma-specific instrument (GSS [11], COMTOL
[12], GQL-15 [13], SIG [14])
It is perhaps not surprising that the glaucoma specific
instruments act as a greater discriminator between glau-
coma patients and controls. There appears to be a stronger
relationship with objective (clinical) measures of disease
state than the generic instruments. Many of the glaucoma
instruments assess symptoms of glaucoma and effects on
activities, but do not include assessment of the importance
of such impacts for the individual. QoL assessment in
glaucoma has been developed further in a handful of
studies that have undertaken utility-based approaches,
such as time trade-off (how much life expectancy would
patients be prepared to give up in exchange for absence of
symptoms), and conjoint analysis (indicating preferences
amongst pairs of options to arrive at rankings of impor-
tance of health/disease states). Such approaches generally
indicate ratings of subjective health status that are more
negative than non-glaucoma patients (but not greatly so),
but which are much more positive than patients who are
blind. This appears to reflect the nature of disease progres-
sion in glaucoma, as many patients have little or no symp-
toms in the early stages of disease.
In order to assess the strengths and weaknesses we will
look at these in more detail.
The Medical Outcomes Study Short Form-36 
(SF-36) [5]
The SF-36 (The Medical Outcomes Study Short Form-36)
is a multi-purpose medical health survey containing 36
questions. The questionnaire is easy to use, takes roughly
10 minutes to complete, and is considered reliable.
Unfortunately there is a weak correlation between all SF-
36 domains and visual acuity or visual field impairment,
which is the end-point of any measure of glaucoma ther-
apy. Therefore, it is not felt that the SF-36 is a suitably
robust assessment tool in glaucoma patients [4].
The Sickness Impact Profile (SIP) [6]
The main aim of the SIP (The Sickness Impact Profile)
development was to provide a measurable instrument of
perceived health status that is robust enough to detect
changes or differences in health status that occur in time
or between groups [6]. There are 136 categories, 12
domains and takes in excess of 30 minutes to complete.
Although the validity and reliability of SIP has been
researched it suggested that the instrument is not easy toPage 2 of 4
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unpractical for use in the clinical setting.
The VF-14 [7]
The VF-14 aims to measure functional impairment in
patients with cataracts. There are 14 functional activity
questions and the instrument is technically straightfor-
ward to use. It has high internal consistency and has a
stronger self-rating correlation than the SIP score. It has
moderate relevance to glaucoma patients in terms of
assessment of visual acuity. However, due to the exclusion
of visual field defect and colour vision, two key indicators
of optic nerve assessment and therefore effectiveness of
glaucoma therapy, the instrument has largely been disre-
garded.
The National Eye Institute Visual Function 
Questionnaire (NEI-VFQ) [8]
The NEI-VFQ (The National Eye Institute Visual Function
Questionnaire) is a 51 item, 12-domain tool that is not
particularly easy to use. The instrument takes 15 minutes
to use. It has been reported that it is more sensitive than
the SF-36 in differentiating patients with glaucoma [4].
The NEI-VFQ is fully validated and is a widely used tool
that allows vision-dependent tasks to be assessed.
The 25-item National Eye Institute Visual 
Function Questionnaire (NEI-VFQ-25) [9]
The NEI-VFQ-25 (The 25-item National Eye Institute Vis-
ual Function
Questionnaire) is a 25 item, 12-domain tool that appears
to be an improved version of its predecessor in that it has
a more clinical emphasis. The instrument takes roughly 5
minutes to use, is reliable and fully validated. However,
the lack of visual field consideration causes this tool to fall
down in comparison to some of the more specific glau-
coma tools. The NEI-VFQ-25 is easy to use which explains
why it has been translated into many languages and forms
the basis of a number of ocular studies. The NEI-VFQ and
NEI-VFQ-25 are used as benchmarks against which more
specific glaucoma QoL tools are compared.
The Activities of Daily Vision Scale (ADVS) [10]
The ADVS (The Activities of Daily Vision Scale) is a 20
item, 12-domain tool that is easy to use. It is reliable and
has good internal consistency [3]. However, it is a cataract
driven tool and does not take into account the loss of
peripheral vision. Although there is good correlation
between other factors, such as visual acuity and visual
field, the exclusion of peripheral field makes it less perti-
nent to glaucoma patients.
The Glaucoma Symptom Scale (GSS) [11]
The GSS (The Glaucoma Symptom Scale) is a 10 item, 2-
domain tool. It uses a cross-section of symptoms, func-
tional impairment, and vision-targeted health related
quality of life assessments among patients with glaucoma
[3]. It is reliable, has good internal consistency, and is
short and easy to use. The GSS was able to discriminate
between persons with and without glaucoma. However,
the instrument did not demonstrate association with
Esterman (binocular) visual field changes. Also, the tool
did not address treatment related factors relevant to QoL
in glaucoma patients.
The Comparison of Ophthalmic Medication for 
Tolerability (COMTOL) [12]
The COMTOL (The Comparison of Ophthalmic Medica-
tion for Tolerability) is a 37 item, 13-domain tool with 4
global questions. This tool is specific for ophthalmic med-
ication tolerability and has good internal consistency,
reproducibility and reliability. The role as a general tool is
therefore very limited.
The Glaucoma Quality of Life-15 (GQL-15) [13]
The GQL-15 (The Glaucoma Quality of Life-15) is a 15
item, 4-domain tool that is short and easy to use. The
instrument is based on the premise that perceived visual
disability (dark adaptation, disability glare, outdoor
mobility tasks and activities using peripheral vision) is
significantly associated with binocular visual field loss.
It has good internal consistency and reliability. The tool
has been shown to demonstrate that difficulties in every-
day life are mirrored by poor performance in a number of
psychophysical tests [3]. The tool does concentrate on the
physical impact of the disease process and does not
address the broader QoL factors. However, if these factors
are addressed then the instrument becomes less user-
friendly in clinical practice.
The Symptom Impact Glaucoma Score (SIG) 
and Glaucoma Health Perceptions index (GHPI) 
[14]
The SIG (The Symptom Impact Glaucoma Score) is a 43
item, 4-domain tool. The GHPI (Glaucoma Health Per-
ceptions index) contains four items that address the phys-
ical, emotional, social and stresses associated with living
with glaucoma. The SIG and GHPI were designed for the
CIGTS study. These instruments are excellent research
tools. Both display demonstrable validity and reliability.
However, they were primarily designed for research and
appear to have limited clinical crossover relevance. The
interviewers underwent an intensive 10-hour training
course before patient interaction commenced.Page 3 of 4
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Conclusion
There are multiple tools/instruments that have been used
to assess the QoL in glaucoma patients. Despite many
reviews there does not appear to be an accepted "industry
standard" tool. The NEI-VFQ and NEI-VFQ-25 remain the
benchmark against which new glaucoma QoL are com-
pared. Many of the tools have their place but often rely
heavily on the physical symptoms rather than considering
social and personal factors.
No one QoL scale has been shown to be ideal and more
research is required to define a more precise and user-
friendly instrument for use in glaucoma patients. Glau-
coma is a disease that is asymptomatic until its very late
stages thus sufferers can be transformed from considering
themselves 'normal' to becoming patients even in the
absence of any obvious functional impairment. This does
of course make assessment of QoL much harder and scales
need to account of this. Personal factors such as worry,
self-identity (and the change the disease state makes to
this), inconvenience of treatment, financial impact of
treatment or alteration in employment/driving need to be
addressed.
We are aware that the generic problem with many of the
QoL instruments is their parochial bias. This is currently
being addressed and will require further review in future
years in order to assess the impact of these non-Western
based QoL instruments [4].
One of the aims of this review was to suggest the most use-
ful QoL scale currently available. One of the key aims
when considering the usability of a QoL tool is to assess
its ease of use. When the QoL instrument attempts to
glean too much information they have a tendency to
become less user-friendly. Ultimately, we feel the NEI-
VFQ and NEI-VFQ-25 will and should remain the com-
parative benchmark for QoL tools. The GQL-15 is proba-
bly the most useful and clinically relevant tool and the
SIG is the most appropriate research tool.
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